4 May 2026[1]
EMA/PRAC/74506/2026
Pharmacovigilance Risk Assessment Committee (PRAC)

New product information wording – Extracts from PRAC recommendations on signals

Adopted at the 7-10 April 2026 PRAC

The product information wording in this document is extracted from the document entitled 'PRAC recommendations on signals' which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found on the webpage for PRAC recommendations on safety signals (in English only).

New text to be added to the product information is underlined. Current text to be deleted is ~~struck through~~.

1. Axicabtagene ciloleucel – Increased risk of brain oedema in primary mediastinal large B-cell lymphoma (PMBCL) patients (EPITT no 20224)

Summary of product characteristics

4.4 Special warnings and precautions for use

Neurologic adverse reactions

Fatal and serious cases of cerebral oedema have been reported in patients treated with Yescarta~~.~~ with most cases occurring in patients with ICANS. The risk for cerebral oedema may be higher in PMBCL patients (see section 4.8).

4.8 Undesirable effects

Table 1: Adverse drug reactions identified with Yescarta

Nervous system disorders

Frequency "Uncommon"

[1] Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.

Cerebral oedema[##]

[Footnote] [##] Most cases of cerebral oedema occurred in patients with ICANS

Description of selected adverse reactions

Neurologic adverse reactions

[…]

In registries, the cerebral oedema event rate in the PMBCL indication was 1.6% overall (2 cases in 129 exposed) compared with 0.7% overall in DLBCL and other lymphoma indications (28 cases in 3876 exposed).

[…]

Package leaflet

4. Possible side effects

Serious side effects

Uncommon (may affect up to 1 in 100 people)

[…]

- Swelling of the brain (cerebral oedema).

2. Ponatinib – Congenital megacolon, maternal exposure during pregnancy (EPITT no 20231)

Summary of product characteristics

4.6 Fertility, pregnancy and lactation

[…]

Pregnancy

Based on limited human data (less than 50 known pregnancy outcomes), cases of congenital megacolon (Hirschsprung's disease) have been reported in children born to women exposed to ponatinib during the first trimester. ~~There are no adequate data from the use of Iclusig in pregnant women.~~ Studies in animals have shown reproductive toxicity (see section 5.3). ~~The potential risk for humans is unknown.~~ Iclusig should not be used during pregnancy unless the clinical condition of the woman requires treatment with ponatinib. ~~Iclusig should be used during pregnancy only when clearly necessary~~. […]

Package leaflet

2. What you need to know before you take Iclusig

[…]

Cases of congenital megacolon, also known as Hirschsprung's disease (a birth defect where nerve cells are missing from part of the baby’s large intestine, resulting in bowel blockage) have been reported in children born to women treated with Iclusig in early pregnancy.